Ocugen prices $35M public offering of 30.4M shares at $1.15 per share

Ocugen, Inc.

Gross proceeds of $35M; net proceeds expected ~$32.6M after underwriting discounts.
Underwriter granted 30-day option to purchase up to 4,565,217 additional shares at same price.
Proceeds to be used for general corporate purposes, working capital, and G&A expenses.
Offering expected to close on or about August 2, 2024; Titan Partners Group sole book-runner.
Financing led by a premier mutual fund with participation from leading life sciences investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.